This is Dimension 4 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Part 4 of 7 — The Patient Marketing Diligence (PMD) Framework
Ask a simple question about any healthcare target: what happens to patient volume if its biggest marketing channel has a bad quarter?
For a lot of targets, the honest answer is that nobody knows, because nobody has checked. That’s the gap Dimension 4 of the Patient Marketing Diligence framework, Channel and Market Concentration Risk, is built to close. Marketing concentration risk won’t kill a deal on its own. But it defines the risk profile of what you’re buying, and it’s rarely priced in explicitly.
What Concentration Actually Means
Concentration shows up in three places: one platform, one campaign type, or one market. A practice getting 85% of its new patients from Google Ads is concentrated by platform. A practice where one branded campaign type drives most of the volume is concentrated by campaign. A multi-location group where a single metro produces most of the leads is concentrated by market.
Lean isn’t automatically bad. Plenty of strong practices run one channel well because it works. The issue isn’t concentration itself, it’s concentration nobody has measured, because that’s where an unpriced single point of failure hides.
The Walk-Away Scenario
The sharpest way to test this is to ask what happens if the main ad account disappears tomorrow. A policy strike, a suspended account, a billing dispute, a Google Ads policy change affecting healthcare advertisers: none of these are exotic, and any of them can take a concentrated channel offline overnight.
Then ask the follow-up that most diligence skips. Who actually controls the account? If an agency or a former employee is the sole owner of access, with no client-side admin control, the practice may not be able to fix the problem quickly, or at all. That’s an operational fragility problem showing up inside a concentration problem, and it’s worth finding before close, not after.
How to Actually Calculate Concentration
This dimension doesn’t require anything exotic either. Start with spend and conversions by platform over the trailing 12 months, then calculate each platform’s share of total new-patient volume, not just its share of spend. The two can differ a lot.
Then repeat the exercise by geography. Pull conversions by market or location from the ad platform’s geographic report, and cross-check against the CRM so the numbers reflect booked patients, not just platform-reported conversions (which is where Dimension 3 comes in). For multi-location targets, it’s worth looking at whether one location is carrying the group.
Finally, look at the regulatory side. A target concentrated in one state is exposed to one set of advertising rules, one licensing regime, and one payer environment. That’s a different kind of concentration, and it deserves its own line in the analysis.
Scoring It
The framework scores this dimension on how much of total patient volume depends on a single channel or market, from diversified across two or more platforms and multiple markets with no single point exceeding roughly 50% of volume at the top, down to total dependency on one channel and one market with no account redundancy at the bottom.
There are two Hard Flags here. First, a single ad account that already carries a policy strike or suspension with no documented contingency. Second, an agency or platform that is the sole owner of account access, with no client-side admin control. Both turn a concentration question into an immediate risk.
Why It Matters for the Deal
Concentration is a discount-rate conversation, not an operational footnote. A target with 80% of volume riding on one platform is a different risk profile than one with three meaningful channels, even if the headline CAC is identical, and the price should reflect that difference.
It also cuts the other way. A concentrated target with clean attribution and room to grow has a legible expansion lever: a second platform, a second market, a channel the seller never tested. That’s value a buyer can underwrite, and it belongs in the growth plan with an owner and a budget rather than as a vague aspiration. Concentration measured well becomes either a price adjustment or a playbook. Concentration ignored is just a surprise.
This is Dimension 4 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Get the full framework: all 7 dimensions, complete scoring criteria, evidence sourcing, and red flag triggers, delivered free.
